Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.81 |
| ▸ | MEN1 | O00255 | 5/20 | 0.81 |
| ▸ | NPC1 | O15118 | 3/20 | 0.80 |
| ▸ | RAB9A | P51151 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | HPGD | P15428 | 1/20 | 0.79 |
| ▸ | ATM | Q13315 | 1/20 | 0.79 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.70 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | THRA | P10827 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | MITF | O75030 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25821827 | 0.90 | BRAF (0.69) | KMT2AMEN1NPC1RAB9ALMNA | |
| SCHEMBL299879 | 0.87 | KMT2A (0.88) | KMT2AMEN1NPC1RAB9ALMNA | |
| SCHEMBL30868371 | 0.87 | KMT2A (0.88) | KMT2AMEN1NPC1RAB9ALMNA | |
| SCHEMBL6396333 | 0.86 | LMNA (0.79) | KMT2AMEN1NPC1RAB9ALMNA | |
| SCHEMBL10943066 | 0.85 | KMT2A (0.94) | KMT2AMEN1NPC1RAB9ALMNA | |
| SCHEMBL7079557 | 0.85 | CYP11B1 (0.74) | KMT2AMEN1RAB9ALMNAHPGD | |
| SCHEMBL1888911 | 0.84 | MAPT (0.77) | KMT2AMEN1NPC1RAB9ALMNA | |
| SCHEMBL25821902 | 0.84 | LMNA (0.70) | KMT2AMEN1NPC1RAB9ALMNA | |
| SCHEMBL94830 | 0.84 | KMT2A (0.88) | KMT2AMEN1NPC1RAB9ALMNA | |
| SCHEMBL27657642 | 0.84 | KMT2A (0.88) | KMT2AMEN1NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427566-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2022-08-30 | — | — | US | disclosed |
| US-20200239444-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2020-07-30 | — | — | US | disclosed |
| US-10717724-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2020-07-21 | — | — | US | disclosed |
| US-20180222888-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2018-08-09 | — | — | US | disclosed |
| US-9969715-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2018-05-15 | — | — | US | disclosed |
| CN-104903293-B | Novel anti-invasive compounds | ABIVAX公司 | 2016-08-24 | — | — | CN | disclosed |
| EP-2900635-B1 | NEW ANTI-INVASIVE COMPOUNDS | ABIVAX (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-20150315173-A1 | NEW ANTI-INVASIVE COMPOUNDS | UNIVERSITE DE MONTPELLIER (FR) | 2015-11-05 | — | — | US | disclosed |
| CN-104903293-A | Novel anti-invasive compounds | ABIVAX | 2015-09-09 | — | — | CN | disclosed |
| EP-2900635-A1 | NEW ANTI-INVASIVE COMPOUNDS | ABIVAX (FR) | 2015-08-05 | — | — | EP | disclosed |
| EP-0622361-B1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-6169095-B1 | FOR PREVENTION AND/OR TREATMENT OF BRADYKININ OR ITS ANALOGUES MEDIATED DISEASES IN THE EYE, SUCH AS ALLERGY, INFLAMMATION AND PAIN OF THE EYE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| US-5922711-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES, SHOCK OR ANALGESICS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| EP-0596406-B1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-12-16 | — | — | EP | disclosed |
| US-5750699-A | HALOGENATING OF CORRESPONDING COMPOUND | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5708173-A | PREPARATION OF SUBSTITUTED QUINOLINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| US-5574042-A | ANTAGONIST FOR BRADYKININS AS ANTIALLERGENS, AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS, SHOCK OR PAIN | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 1996-11-12 | — | — | US | disclosed |
| US-5563162-A | CAN BE ADMINISTERD FOR THE TREATMENT OF ALLERGY, INFLAMMATION, AUTOIMMUNE DISEASES, SHOCK OR PAIN IN ANIMALS AND HUMANS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-10-08 | — | — | US | disclosed |
| EP-0622361-A1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-02 | — | — | EP | disclosed |
| EP-0596406-A1 | Imidazo (1,2-a) Pyridines as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222888-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | PRMT7, PRMT6, RRM2 | KMT2A 2111/4885MEN1 493/4885NPC1 1881/4885 |
| US-20150315173-A1 | NEW ANTI-INVASIVE COMPOUNDS | MIF, MMP7, MMP8 | KMT2A 3485/4885MEN1 830/4885NPC1 520/4885 |
| US-10717724-B2 | Compounds useful for treating cancer | PRMT7, PRMT6, RRM2 | KMT2A 2111/4885MEN1 493/4885NPC1 1881/4885 |
| US-20200239444-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | PRMT7, PRMT6, RRM2 | KMT2A 2003/4885MEN1 542/4885NPC1 2247/4885 |
| US-11427566-B2 | Compounds useful for treating cancer | PRMT7, PRMT6, RRM2 | KMT2A 2003/4885MEN1 542/4885NPC1 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.